Cargando…

Monoclonal Antibody against G Glycoprotein Increases Respiratory Syncytial Virus Clearance In Vivo and Prevents Vaccine-Enhanced Diseases

Respiratory syncytial virus (RSV) is a common cause of lower respiratory tract illness in infants, young children, and the elderly. The G glycoprotein plays a role in host cell attachment and also modulates the host immune response, thereby inducing disease pathogenesis. We generated two monoclonal...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Hyo-Jeong, Lee, Jeong-Yoon, Park, Min-Hee, Kim, Joo-Young, Chang, Jun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5226777/ https://www.ncbi.nlm.nih.gov/pubmed/28076422 http://dx.doi.org/10.1371/journal.pone.0169139

Ejemplares similares

The Use of Humanized Monoclonal Antibodies for the Prevention of Respiratory Syncytial Virus Infection
por: Lanari, Marcello, et al.
Publicado: (2013)

Features of the Human Antibody Response against the Respiratory Syncytial Virus Surface Glycoprotein G
por: Borochova, Kristina, et al.
Publicado: (2020)

Product review on the monoclonal antibody palivizumab for prevention of respiratory syncytial virus infection
por: Resch, Bernhard
Publicado: (2017)

Combination Therapy Using Monoclonal Antibodies against Respiratory Syncytial Virus (RSV) G Glycoprotein Protects from RSV Disease in BALB/c Mice
por: Caidi, Hayat, et al.
Publicado: (2012)

Purification and characterization of monoclonal IgG antibodies recognizing Ebola virus glycoprotein
por: Han, Baek-Sang, et al.
Publicado: (2018)

Replication and Clearance of Respiratory Syncytial Virus : Apoptosis Is an Important Pathway of Virus Clearance after Experimental Infection with Bovine Respiratory Syncytial Virus
por: Viuff, Birgitte, et al.
Publicado: (2002)

Dual Role of Respiratory Syncytial Virus Glycoprotein Fragment as a Mucosal Immunogen and Chemotactic Adjuvant
por: Kim, Sol, et al.
Publicado: (2012)

Development of Luciferase Immunoprecipitation Systems (LIPS) Assay to Detect IgG Antibodies against Human Respiratory Syncytial Virus G-Glycoprotein
por: Crim, Roberta Lynne, et al.
Publicado: (2019)

Monoclonal Antibody for the Prevention of Respiratory Syncytial Virus in Infants and Children: A Systematic Review and Network Meta-analysis
por: Sun, Mingyao, et al.
Publicado: (2023)

Engineering the surface properties of a human monoclonal antibody prevents self-association and rapid clearance in vivo
por: Dobson, Claire L., et al.
Publicado: (2016)

Ephedrae Herba and Cinnamomi Cortex interactions with G glycoprotein inhibit respiratory syncytial virus infectivity
por: Fujikane, Aya, et al.
Publicado: (2022)

Structural basis of respiratory syncytial virus subtype-dependent neutralization by an antibody targeting the fusion glycoprotein
por: Tian, Daiyin, et al.
Publicado: (2017)

Universal vaccine against respiratory syncytial virus A and B subtypes
por: Lee, Jeong-Yoon, et al.
Publicado: (2017)

Respiratory Syncytial Virus Prevention through Monoclonal Antibodies: A Cross-Sectional Study on Knowledge, Attitudes, and Practices of Italian Pediatricians
por: Riccò, Matteo, et al.
Publicado: (2023)

Subtractive Immunization as a Method to Develop Respiratory Syncytial Virus (RSV)—Specific Monoclonal Antibodies
por: Jacobs, Lotte, et al.
Publicado: (2023)

Antibody development for preventing the human respiratory syncytial virus pathology
por: Soto, Jorge A., et al.
Publicado: (2020)

Role of oligosaccharides in the structure and function of respiratory syncytial virus glycoproteins
por: Lambert, Dennis M.
Publicado: (1988)

Interactions of heparin with key glycoproteins of human respiratory syncytial virus
por: Shi, Deling, et al.
Publicado: (2023)

Sublingual Immunization With an RSV G Glycoprotein Fragment Primes IL-17-Mediated Immunopathology Upon Respiratory Syncytial Virus Infection
por: Cheon, In Su, et al.
Publicado: (2019)

Preparation and Evaluation of the Fully Humanized Monoclonal Antibody GD-mAb Against Respiratory Syncytial Virus
por: Tian, Puyuan, et al.
Publicado: (2019)

Estimating the cost-effectiveness of maternal vaccination and monoclonal antibodies for respiratory syncytial virus in Kenya and South Africa
por: Koltai, Mihaly, et al.
Publicado: (2023)

Helical ordering of envelope‐associated proteins and glycoproteins in respiratory syncytial virus
por: Conley, Michaela J, et al.
Publicado: (2021)

Caspase-1 Independent Viral Clearance and Adaptive Immunity Against Mucosal Respiratory Syncytial Virus Infection
por: Shim, Ye Ri, et al.
Publicado: (2015)

Role of G2-S16 Polyanionic Carbosilane Dendrimer in the Prevention of Respiratory Syncytial Virus Infection In Vitro and In Vivo in Mice
por: Rodriguez-Izquierdo, Ignacio, et al.
Publicado: (2021)

Influenza virus glycoprotein-reactive human monoclonal antibodies
por: Li, Yanbai, et al.
Publicado: (2020)

The Complexity of Antibody Responses Elicited against the Respiratory Syncytial Virus Glycoproteins in Hospitalized Children Younger than 2 Years
por: Trento, Alfonsina, et al.
Publicado: (2017)

Introduction and clearance of beta‐glucan in the downstream processing of monoclonal antibodies
por: Kluters, Simon, et al.
Publicado: (2021)

Engineered mRNA-expressed antibodies prevent respiratory syncytial virus infection
por: Tiwari, Pooja Munnilal, et al.
Publicado: (2018)

Iterative structure-based improvement of a respiratory syncytial virus fusion glycoprotein vaccine
por: Joyce, M. Gordon, et al.
Publicado: (2016)

The prevention of respiratory syncytial virus infection
por: Bollani, L, et al.
Publicado: (2014)

Plasmacytoid dendritic cells inhibit pulmonary immunopathology and promote clearance of respiratory syncytial virus
por: Smit, Joost J., et al.
Publicado: (2006)

A33 Respiratory syncytial virus group B evolutionary trends in the attachment (G) glycoprotein in Kilifi, Kenya, 2003–2015
por: Kamau, Everlyn, et al.
Publicado: (2018)

Plasma clearance of an antibody--enzyme conjugate in ADEPT by monoclonal anti-enzyme: its effect on prodrug activation in vivo.
por: Rogers, G. T., et al.
Publicado: (1995)

Evaluation of respiratory syncytial virus IgG antibody dynamics in mother-infant pairs cohort
por: Yildiz, Mehmet, et al.
Publicado: (2020)

Requirements for Human Respiratory Syncytial Virus Glycoproteins in Assembly and Egress from Infected Cells
por: Batonick, Melissa, et al.
Publicado: (2011)

Structure-Based Design of Head-Only Fusion Glycoprotein Immunogens for Respiratory Syncytial Virus
por: Boyington, Jeffrey C., et al.
Publicado: (2016)

Stability Characterization of a Vaccine Antigen Based on the Respiratory Syncytial Virus Fusion Glycoprotein
por: Flynn, Jessica A., et al.
Publicado: (2016)

Extension of the in vivo half-life of endostatin and its improved anti-tumor activities upon fusion to a humanized antibody against tumor-associated glycoprotein 72 in a mouse model of human colorectal carcinoma
por: Lee, Sang-Hyun, et al.
Publicado: (2015)

Effect of respiratory syncytial virus on the growth of hepatocellular carcinoma cell-lines
por: Choi, Song Hee, et al.
Publicado: (2015)

Respiratory Syncytial Virus Prevention: A New Era of Vaccines
por: Lee, Calvin Yee Fen, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_l3mv997oub1qh7j8tbmukbdtgq